Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19

Next Previous
X
Search
Trial Profile

A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 23 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Molnupiravir (Primary) ; Molnupiravir (Primary)
  • Indications COVID 2019 infections; COVID-19 respiratory infection
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MK-4482-001; MOVe-IN
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 26 Jan 2022 This trial has been completed in Poland, according to European Clinical Trials Database record.
    • 04 Dec 2021 This trial has been completed in Sweden, according to European Clinical Trials Database record.
    • 09 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top